EMERSON PERIN to Bone Marrow Transplantation
This is a "connection" page, showing publications EMERSON PERIN has written about Bone Marrow Transplantation.
Connection Strength
3.002
-
Effect of transendocardial delivery of autologous bone marrow mononuclear cells on functional capacity, left ventricular function, and perfusion in chronic heart failure: the FOCUS-CCTRN trial. JAMA. 2012 Apr 25; 307(16):1717-26.
Score: 0.317
-
A randomized, controlled study of autologous therapy with bone marrow-derived aldehyde dehydrogenase bright cells in patients with critical limb ischemia. Catheter Cardiovasc Interv. 2011 Dec 01; 78(7):1060-7.
Score: 0.299
-
A randomized study of transendocardial injection of autologous bone marrow mononuclear cells and cell function analysis in ischemic heart failure (FOCUS-HF). Am Heart J. 2011 Jun; 161(6):1078-87.e3.
Score: 0.299
-
A dosing study of bone marrow mononuclear cells for transendocardial injection in a pig model of chronic ischemic heart disease. Tex Heart Inst J. 2011; 38(3):219-24.
Score: 0.291
-
[Sustained improvement in symptoms and exercise capacity up to six months after autologous transendocardial transplantation of bone marrow mononuclear cells in patients with severe ischemic heart disease]. Arq Bras Cardiol. 2005 May; 84(5):360-6.
Score: 0.198
-
Transendocardial injection of autologous mononuclear bone marrow cells in end-stage ischemic heart failure patients: one-year follow-up. Int J Cardiol. 2004 Jun; 95 Suppl 1:S45-6.
Score: 0.185
-
Transendocardial, autologous bone marrow cell transplantation for severe, chronic ischemic heart failure. Circulation. 2003 May 13; 107(18):2294-302.
Score: 0.171
-
TIME Trial: Effect of Timing of Stem Cell Delivery Following ST-Elevation Myocardial Infarction on the Recovery of Global and Regional Left Ventricular Function: Final 2-Year Analysis. Circ Res. 2018 02 02; 122(3):479-488.
Score: 0.118
-
Evaluation of Cell Therapy on Exercise Performance and Limb Perfusion in Peripheral Artery Disease: The CCTRN PACE Trial (Patients With Intermittent Claudication Injected With ALDH Bright Cells). Circulation. 2017 Apr 11; 135(15):1417-1428.
Score: 0.111
-
Association between High Endocardial Unipolar Voltage and Improved Left Ventricular Function in Patients with Ischemic Cardiomyopathy. Tex Heart Inst J. 2016 Aug; 43(4):291-6.
Score: 0.107
-
Bone marrow cell characteristics associated with patient profile and cardiac performance outcomes in the LateTIME-Cardiovascular Cell Therapy Research Network (CCTRN) trial. Am Heart J. 2016 09; 179:142-50.
Score: 0.107
-
Bone marrow characteristics associated with changes in infarct size after STEMI: a biorepository evaluation from the CCTRN TIME trial. Circ Res. 2015 Jan 02; 116(1):99-107.
Score: 0.095
-
Effect of the use and timing of bone marrow mononuclear cell delivery on left ventricular function after acute myocardial infarction: the TIME randomized trial. JAMA. 2012 Dec 12; 308(22):2380-9.
Score: 0.083
-
Effect of intracoronary delivery of autologous bone marrow mononuclear cells 2 to 3 weeks following acute myocardial infarction on left ventricular function: the LateTIME randomized trial. JAMA. 2011 Nov 16; 306(19):2110-9.
Score: 0.077
-
CD34(+) cell infusion after ST elevation myocardial infarction is associated with improved perfusion and is dose dependent. Am Heart J. 2011 Jan; 161(1):98-105.
Score: 0.073
-
Intramyocardial injection of autologous bone marrow mononuclear cells for patients with chronic ischemic heart disease and left ventricular dysfunction (First Mononuclear Cells injected in the US [FOCUS]): Rationale and design. Am Heart J. 2010 Aug; 160(2):215-23.
Score: 0.071
-
LateTIME: a phase-II, randomized, double-blinded, placebo-controlled, pilot trial evaluating the safety and effect of administration of bone marrow mononuclear cells 2 to 3 weeks after acute myocardial infarction. Tex Heart Inst J. 2010; 37(4):412-20.
Score: 0.068
-
Rationale and design for TIME: A phase II, randomized, double-blind, placebo-controlled pilot trial evaluating the safety and effect of timing of administration of bone marrow mononuclear cells after acute myocardial infarction. Am Heart J. 2009 Sep; 158(3):356-63.
Score: 0.066
-
[Diabetic and nondiabetic patients respond differently to transendocardial injection of bone marrow mononuclear cells: findings from prospective clinical trials in "no-option" patients]. Rev Esp Cardiol. 2008 Jun; 61(6):635-9.
Score: 0.061
-
Adult bone marrow-derived cells for cardiac repair: a systematic review and meta-analysis. Arch Intern Med. 2007 May 28; 167(10):989-97.
Score: 0.057
-
Transendocardial autologous bone marrow mononuclear cell injection in ischemic heart failure: postmortem anatomicopathologic and immunohistochemical findings. Circulation. 2005 Jul 26; 112(4):521-6.
Score: 0.050
-
Catheter-based transendocardial delivery of autologous bone-marrow-derived mononuclear cells in patients listed for heart transplantation. Tex Heart Inst J. 2004; 31(3):214-9.
Score: 0.045
-
Identification of cardiovascular risk factors associated with bone marrow cell subsets in patients with STEMI: a biorepository evaluation from the CCTRN TIME and LateTIME clinical trials. Basic Res Cardiol. 2017 01; 112(1):3.
Score: 0.027
-
Identification of Bone Marrow Cell Subpopulations Associated With Improved Functional Outcomes in Patients With Chronic Left Ventricular Dysfunction: An Embedded Cohort Evaluation of the FOCUS-CCTRN Trial. Cell Transplant. 2016; 25(9):1675-1687.
Score: 0.026